SENTARA COMMUNITY PLAN
(MEDICAID)

PHARMACY PRIOR AUTHORIZATION/STEP-EDIT REQUEST*

Directions: **The prescribing physician must sign and clearly print name (preprinted stamps not valid) on this request**. All other information may be filled in by office staff; **fax to 1-800-750-9692**. No additional phone calls will be necessary if all information (including phone and fax #s) on this form is correct. **If the information provided is not complete, correct, or legible, the authorization process can be delayed.**

The Sentara Health Plans Oncology Program is administered by OncoHealth

- **For any oncology indications**, the most efficient way to submit a prior authorization request is through the **OncoHealth OneUM Provider Portal** at https://oneum.oncohealth.us. Fax to **1-800-264-6128.**

OncoHealth can also be contacted at Phone: 1-888-916-2616

Drug Requested: Kineret™ (anakinra) **(Non-Preferred)**

MEMBER & PRESCRIBER INFORMATION: Authorization may be delayed if incomplete.

Member Name: _____

Member Sentara #: _____ **Date of Birth:** _____

Prescriber Name: _____

Prescriber Signature: _____ **Date:** _____

Office Contact Name: _____

Phone Number: _____ **Fax Number:** _____

NPI #: _____

DRUG INFORMATION: Authorization may be delayed if incomplete.

Drug Name/Form/Strength: _____

Dosing Schedule: _____ **Length of Therapy**: _____

Diagnosis: _____ **ICD Code, if applicable:** _____

Weight (if applicable): _____ **Date weight obtained:** _____

Recommended dose and quantity limit: One syringe per day (maximum quantity 30/30 days)

CLINICAL CRITERIA: Check below all that apply. All criteria must be met for approval. To support each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be provided or request may be denied.

- ❑ **Diagnosis: Moderate to severe Active Rheumatoid Arthritis**
  - ❑ Member is 18 years of age or older

(Continued on next page)

- ❑ Member has a diagnosis of moderate to severely active rheumatoid arthritis
- ❑ Trial and failure of one conventional synthetic disease modifying anti-rheumatic drug (csDMARD) (e.g. methotrexate, azathioprine, hydroxychloroquine, penicillamine, sulfasalazine, leflunomide, etc.)
- ❑ Trial and failure of **BOTH** of the preferred biologics below:

❑ adalimumab-adbm (Boehringer Ingelheim) **OR** Hadlima® (adalimumab-bwwd)	❑ Enbrel®

❑ Diagnosis: Cryopyrin-Associated Periodic Syndromes (CAPS)
Approvable with confirmation of this diagnosis.

- ❑ Treatment of Neonatal-Onset Multisystem Inflammatory Disease

❑ Diagnosis: Deficiency of Interleukin-1 Receptor Antagonist (DIRA)
Approvable with confirmation of this diagnosis.

- ❑ Deficiency of Interleukin-1 Receptor Antagonist (DIRA)

Medication being provided by (check applicable box(es) below):

❑ **Physician's office** **OR** ❑ **Specialty Pharmacy – PropriumRx**

*****Use of samples to initiate therapy does not meet step edit/ preauthorization criteria.*****

****Previous therapies will be verified through pharmacy paid claims or submitted chart notes.****

REVISED/UPDATED/REFORMATTED:~~11/19/2018; 12/9/2018;4/15/2018; 7/19/2021; 01/05/2022; 1/6/2022; 7/8/2022 6/20/2023; 11/7/2023; 2/28/2025; 10/17/2025; 12/16/2025; 1/20/2026;~~ **7.14.2026**